Suppr超能文献

基于高斯荧光素酶的人诺如病毒蛋白酶报告系统的开发:诺沃克病毒蛋白酶前体的细胞类型特异性概况及抑制剂评估

Development of a Gaussia luciferase-based human norovirus protease reporter system: cell type-specific profile of Norwalk virus protease precursors and evaluation of inhibitors.

作者信息

Qu Lin, Vongpunsawad Sompong, Atmar Robert L, Prasad B V Venkataram, Estes Mary K

机构信息

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.

Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.

出版信息

J Virol. 2014 Sep;88(18):10312-26. doi: 10.1128/JVI.01111-14. Epub 2014 Jul 9.

Abstract

UNLABELLED

Norwalk virus (NV) is the prototype strain of human noroviruses (HuNoVs), a group of positive-strand RNA viruses in the Caliciviridae family and the leading cause of epidemic gastroenteritis worldwide. Investigation of HuNoV replication and development of antiviral therapeutics in cell culture remain challenging tasks. Here, we present NoroGLuc, a HuNoV protease reporter system based on a fusion of NV p41 protein with a naturally secreted Gaussia luciferase (GLuc), linked by the p41/p22 cleavage site for NV protease (Pro). trans cleavage of NoroGLuc by NV Pro or Pro precursors results in release and secretion of an active GLuc. Using this system, we observed a cell type-specific activity profile of NV Pro and Pro precursors, suggesting that the activity of NV Pro is modulated by other viral proteins in the precursor forms and strongly influenced by cellular factors. NoroGLuc was also cleaved by Pro and Pro precursors generated from replication of NV stool RNA in transfected cells, resulting in a measurable increase of secreted GLuc. Truncation analysis revealed that the N-terminal membrane association domain of NV p41 is critical for NoroGLuc activity. Although designed for NV, a genogroup GI.1 norovirus, NoroGLuc also efficiently detects Pro activities from GII.3 and GII.4 noroviruses. At noncytotoxic concentrations, protease inhibitors ZnCl2 and Nα-p-tosyl-l-lysine chloromethyl ketone (TLCK) exhibited dose-dependent inhibitory effects on a GII.4 Pro by NoroGLuc assay. These results establish NoroGLuc as a pan-genogroup HuNoV protease reporter system that can be used for the study of HuNoV proteases and precursors, monitoring of viral RNA replication, and evaluation of antiviral agents.

IMPORTANCE

Human noroviruses are the leading cause of epidemic gastroenteritis worldwide. Currently, there are no vaccines or antiviral drugs available to counter these highly contagious viruses. These viruses are currently noncultivatable in cell culture. Here, we report the development of a novel cell-based reporter system called NoroGLuc that can be used for studying norovirus replication and also for screening/evaluation of antiviral agents. This system is based on the fusion between viral protein p41 and a naturally secreted Gaussia luciferase (GLuc) with a cleavage site that can be recognized by the viral protease. Cleavage of this fusion protein by the viral protease results in the release and secretion of an active GLuc. Using NoroGLuc, we demonstrated a cell type-specific activity profile of the viral protease and its precursors and dose-dependent inhibitory effects of two protease inhibitors. This novel reporter system should be useful in probing norovirus replication and evaluating antiviral agents.

摘要

未标记

诺如病毒(NV)是人类诺如病毒(HuNoVs)的原型毒株,人类诺如病毒是杯状病毒科中的一组正链RNA病毒,是全球流行性肠胃炎的主要病因。在细胞培养中研究HuNoV复制及开发抗病毒疗法仍然是具有挑战性的任务。在此,我们展示了NoroGLuc,这是一种基于NV p41蛋白与天然分泌的高斯荧光素酶(GLuc)融合的HuNoV蛋白酶报告系统,二者通过NV蛋白酶(Pro)的p41/p22切割位点相连。NV Pro或Pro前体对NoroGLuc的反式切割导致活性GLuc的释放和分泌。利用该系统,我们观察到NV Pro和Pro前体具有细胞类型特异性的活性谱,这表明NV Pro的活性在前体形式中受到其他病毒蛋白的调节,并受到细胞因子的强烈影响。NoroGLuc也被转染细胞中NV粪便RNA复制产生的Pro和Pro前体切割,导致分泌的GLuc有可测量的增加。截短分析表明,NV p41的N端膜结合结构域对NoroGLuc活性至关重要。尽管NoroGLuc是为NV(一种基因群GI.1诺如病毒)设计的,但它也能有效检测GII.3和GII.4诺如病毒的Pro活性。在无细胞毒性浓度下,蛋白酶抑制剂ZnCl2和Nα-p-甲苯磺酰-L-赖氨酸氯甲基酮(TLCK)通过NoroGLuc检测对GII.4 Pro表现出剂量依赖性抑制作用。这些结果确立了NoroGLuc作为一种泛基因群HuNoV蛋白酶报告系统,可用于研究HuNoV蛋白酶和前体、监测病毒RNA复制以及评估抗病毒药物。

重要性

人类诺如病毒是全球流行性肠胃炎的主要病因。目前,尚无疫苗或抗病毒药物可对抗这些高传染性病毒。这些病毒目前无法在细胞培养中培养。在此,我们报告了一种名为NoroGLuc的新型细胞报告系统的开发,该系统可用于研究诺如病毒复制,也可用于筛选/评估抗病毒药物。该系统基于病毒蛋白p41与天然分泌的高斯荧光素酶(GLuc)的融合,其具有一个可被病毒蛋白酶识别的切割位点。病毒蛋白酶对这种融合蛋白的切割导致活性GLuc的释放和分泌。利用NoroGLuc,我们展示了病毒蛋白酶及其前体的细胞类型特异性活性谱以及两种蛋白酶抑制剂的剂量依赖性抑制作用。这种新型报告系统应有助于探究诺如病毒复制和评估抗病毒药物。

相似文献

2
Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response.
J Virol. 2016 Sep 12;90(19):8906-23. doi: 10.1128/JVI.01425-16. Print 2016 Oct 1.
3
Characterization and inhibition of norovirus proteases of genogroups I and II using a fluorescence resonance energy transfer assay.
Virology. 2012 Feb 20;423(2):125-33. doi: 10.1016/j.virol.2011.12.002. Epub 2011 Dec 24.
4
The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.
Antimicrob Agents Chemother. 2014 Aug;58(8):4675-81. doi: 10.1128/AAC.02546-13. Epub 2014 Jun 2.
5
Selection and Characterization of Rupintrivir-Resistant Norwalk Virus Replicon Cells .
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00201-18. Print 2018 May.
6
Replication and packaging of Norwalk virus RNA in cultured mammalian cells.
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10327-32. doi: 10.1073/pnas.0408529102. Epub 2005 Jul 7.
7
GII.4 Norovirus Protease Shows pH-Sensitive Proteolysis with a Unique Arg-His Pairing in the Catalytic Site.
J Virol. 2019 Mar 5;93(6). doi: 10.1128/JVI.01479-18. Print 2019 Mar 15.
8
Norovirus Protease Structure and Antivirals Development.
Viruses. 2021 Oct 14;13(10):2069. doi: 10.3390/v13102069.
9
Development of a stable Gaussia luciferase enterovirus 71 reporter virus.
J Virol Methods. 2015 Jul;219:62-66. doi: 10.1016/j.jviromet.2015.03.020. Epub 2015 Apr 2.
10
Norwalk virus RNA is infectious in mammalian cells.
J Virol. 2007 Nov;81(22):12238-48. doi: 10.1128/JVI.01489-07. Epub 2007 Sep 12.

引用本文的文献

3
Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response.
J Virol. 2016 Sep 12;90(19):8906-23. doi: 10.1128/JVI.01425-16. Print 2016 Oct 1.
4
Antiviral targets of human noroviruses.
Curr Opin Virol. 2016 Jun;18:117-25. doi: 10.1016/j.coviro.2016.06.002. Epub 2016 Jun 17.
5
Current tools for norovirus drug discovery.
Expert Opin Drug Discov. 2016 Jun;11(6):529-41. doi: 10.1080/17460441.2016.1178231. Epub 2016 May 2.

本文引用的文献

1
Naphthalene-sulfonate inhibitors of human norovirus RNA-dependent RNA-polymerase.
Antiviral Res. 2014 Feb;102:23-8. doi: 10.1016/j.antiviral.2013.11.016. Epub 2013 Dec 4.
2
Determination of the 50% human infectious dose for Norwalk virus.
J Infect Dis. 2014 Apr 1;209(7):1016-22. doi: 10.1093/infdis/jit620. Epub 2013 Nov 18.
4
Epidemiology of human noroviruses and updates on vaccine development.
Curr Opin Gastroenterol. 2014 Jan;30(1):25-33. doi: 10.1097/MOG.0000000000000022.
5
Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.
Bioorg Med Chem Lett. 2013 Dec 1;23(23):6317-20. doi: 10.1016/j.bmcl.2013.09.070. Epub 2013 Sep 30.
7
Effects and clinical significance of GII.4 Sydney norovirus, United States, 2012-2013.
Emerg Infect Dis. 2013 Aug;19(8):1231-8. doi: 10.3201/eid1908.130458.
8
Enzyme kinetics of the human norovirus protease control virus polyprotein processing order.
Virology. 2013 Sep;444(1-2):218-24. doi: 10.1016/j.virol.2013.06.013. Epub 2013 Jul 11.
9
Noroviruses: The Most Common Pediatric Viral Enteric Pathogen at a Large University Hospital After Introduction of Rotavirus Vaccination.
J Pediatric Infect Dis Soc. 2013 Mar;2(1):57-60. doi: 10.1093/jpids/pis070. Epub 2012 Aug 3.
10
Norovirus and medically attended gastroenteritis in U.S. children.
N Engl J Med. 2013 Mar 21;368(12):1121-30. doi: 10.1056/NEJMsa1206589.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验